Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections
Open Access
- 21 November 2025
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10305
Abstract
Vaccination and prior infection elicit neutralizing antibodies targeting SARS-CoV-2, yet the quantitative relationship between serum antibodies and infection risk against viral variants remains uncertain, particularly in underrepresented regions. We investigated the protective correlation of pre-exposure serum neutralizing antibody levels, employing a panel of SARS-CoV-2 pseudoviruses (Omicron BA.1, Omicron BA.2, and ancestral D614G), and Spike-binding antibody levels, with symptomatic BA.1 or BA.2 SARS-CoV-2 infections and overall infection, in 345 household contacts from a SARS-CoV-2 household cohort study in Nicaragua. A four-fold increase in homotypic-neutralizing (e.g., BA.1-neutralizing vs. BA.1 exposure) titers was correlated with protection from symptomatic infections (BA.1 protection: 28% [95%CI 12–42%]; BA.2 protection: 43% [20–62%]), and ancestral-neutralizing titers were also correlated with protection from either variant, but only at higher average levels than homotypic. Mediation analyses revealed that homotypic and D614G-neutralizing antibodies mediated protection from infection and symptomatic infection both from prior infection and vaccination. These findings underscore the importance of monitoring variant-specific antibody responses and highlight that antibodies targeting circulating strains may be more predictive of protection from infection. Nevertheless, ancestral-strain-neutralizing antibodies remain relevant as a correlate of protection. Our study emphasizes the need for continued efforts to assess antibody correlates of protection.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV019355, INV019355)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400006C, 75N93021C00016)
- Open Philantropy; Supported by the Biosciences Initiative at the University of Michigan through a Mid-career Biosciences Faculty Achievement Award.
- NIH SARS-CoV-2 Assessment of Viral Evolution (SAVE) Program -
This publication has 32 references indexed in Scilit:
- Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updatesNature Communications, 2024
- Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trialNature Communications, 2024
- Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workersVaccine, 2024
- Antibody correlates of protection against Delta infection after vaccination: A nested case-control within the UK-based SIREN studyJournal of Infection, 2023
- Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2Nature Communications, 2023
- Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workersNature Communications, 2023
- Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort studyThe Lancet Microbe, 2023
- Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trialNature Communications, 2023
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariantsCell, 2022
- Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 MortalityCell, 2020